Candel Therapeutics
CADL | NASDAQ
$5.81
-$0.39 (-6.29%)
At close: Nov 16, 2026, 4:00 PM ET
$5.76
-$0.05 (-0.86%)
After-hours:
Nov 16, 2026, 7:55 PM ET
-6.29%
(1D)No price chart data available for 1D timeframe.
Rating
34.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #661/1021 (Top 65%)
Key Statistics
Market Data
Market Cap $455.77M
1D Range
5.73 6.23
52W Range
4.42 13.75
Valuation (TTM)
PE -3.93
PB 3.46
EV/EBITDA -2.68
Valuation (NTM)
Forward PE N/A
Forward PEG -0.02
Price Target $23.00
Cash Flow
FCF Yield -15.4%
SBC Adj. FCF Yield -17.2%
SBC Impact -11.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
-90.0%
Dil EPS 3Y | 5Y 10.2% |
-14.6%
FCF 3Y | 5Y -47.0% |
-19.4%
Returns
ROA -47.0%
ROE -88.6%
ROIC -44.4%
Financial Health
Net Cash
$201.55M
Current Ratio 7.57
Interest Coverage -13.30
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-...
Sector Healthcare
Industry Biotechnology
Employees 55
IPO Date Jul 27, 2021
Website www.candeltx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
6
Consensus
Buy
Price Target
$23.00
Upside
+295.87%
Buy (6)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CADL